加载中
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
前收盘价
US$3.83
+US$0.04 · +1.06%
盘中时间采用ET。市场数据可能有所延迟。
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
日内区间
当前US$3.83
52周区间
当前US$3.83
盘中时间采用ET。市场数据可能有所延迟。
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
日内区间
当前US$3.83
52周区间
当前US$3.83
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 782.6万 USD | 1872万 USD | 3124.9万 USD | 2975.2万 USD | 676.1万 USD |
| 销货成本 | 209.1万 USD | 279.2万 USD | 1808.1万 USD | 1196万 USD | 471.3万 USD |
| 毛利 | 573.5万 USD | 1592.8万 USD | 1316.8万 USD | 1779.2万 USD | 204.8万 USD |
| 研究与开发 | 5264.5万 USD | 3358.6万 USD | 9838.4万 USD | 7781.3万 USD | 4381.3万 USD |
| 销售、一般及管理费用 | 2197.2万 USD | 2220.3万 USD | 3109.8万 USD | 2513.3万 USD | 2361.9万 USD |
| 营业费用 | 8211万 USD | 1.58亿 USD | 1.11亿 USD | 1.08亿 USD | 9177.1万 USD |
| 利息收入 | 763.7万 USD | 795.3万 USD | — | — | — |
| 折旧和摊销 | 45.4万 USD | 80.7万 USD | 86.3万 USD | 79.7万 USD | 92.3万 USD |
| 营业利润 | −7637.5万 USD | −1.42亿 USD | −9735.7万 USD | −8985.4万 USD | −8972.3万 USD |
| 净利润 | −6492.3万 USD | −1.32亿 USD | −8848.1万 USD | −8690.8万 USD | −9086.5万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$10.60
上涨空间 176.76%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2567.23万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1190.31万0.02%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF887.06万0.01%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO412.24万0.02%180亿 USD0.06%US$112.66+0.50%
State Street SPDR S&P Pharmaceuticals ETFXPH391.39万0.85%4.62亿 USD0.35%US$64.65+1.60%
iShares Russell 2000 Growth ETFIWO362.74万0.03%139.17亿 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB330.74万0.03%108.2亿 USD0.44%US$206.49+3.00%
Fidelity Enhanced Small Cap ETFFESM320.01万0.05%64.1亿 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
